RESUMEN
OBJECTIVE: The causes for the variable susceptibility of renal clearance (CLr) and bioavailability (F) of drugs in renal impairment are still unknown. We investigated whether the impact of chronic kidney disease (CKD) on non-renal clearance (CLnr) or F can be appraised when drug administration is by the oral route only in dedicated renal impairment studies (DRIS), as is routinely done when developing drugs intended for oral use. MATERIALS AND METHODS: A literature search on DRIS administering drugs orally only or orally and intravenously was conducted. Seven drugs administered orally only with notable CLnr and 2 drugs administered by the oral and intravenous routes with negligible CLnr were identified. Regressions of oral clearance (CL/F), normalized by absolute bioavailability in healthy subjects (F1), on CLr were performed for the drugs with notable non-renal elimination to determine the impact of CKD on CLnr. Regressions of CL/F and CL on CLr were conducted for the drugs with negligible CLnr to determine F. RESULTS: Excessive variability in CL/F and CLr precluded evaluation of CLnr for 1 drug with notable CLnr and F1 < 0.01. A categorization based on the susceptibility of CLnr to CKD appeared possible for the 6 drugs with notable non-renal elimination if the parameters of the F1 normalized regressions of CL/F on CLr are taken at face value, i.e., if equality of F and F1 is assumed. However, the true relationship between F and F1 in subjects with varying renal function is unknowable for drugs with significant CLnr when administered orally only. F of drugs with significant CLnr may be altered by a reduced activity of uptake-transporters and/or enzymes so that in renal impaired subjects both absorption and first pass metabolism of intact drug may be reduced relative to healthy subjects, making it impossible to predict whether F in the former or latter population is greater. Bioavailability of drugs with negligible CLnr may depend primarily on the integrity of uptake-transporters so that F in healthy subjects is expected to be greater than in renal impaired subjects. Apparently accurate estimates of F for drugs with negligible CLnr may be obtained from DRIS with oral administration by using the reciprocal of the slope of the regressions. CONCLUSION: A reliable assessment of the impact of CKD on CLnr for drugs with significant non-renal elimination requires information after oral and intravenous administration in the same DRIS study. However, apparently accurate estimates of F for drugs with negligible non-renal elimination may be obtained in DRIS with oral drug administration only, but validation of the proposed method with other drugs exhibiting negligible non-renal elimination and variable F1 is required.
Asunto(s)
Insuficiencia Renal Crónica , Insuficiencia Renal , Humanos , Preparaciones Farmacéuticas , Disponibilidad Biológica , Pruebas de Función Renal , Insuficiencia Renal Crónica/diagnóstico , Administración OralAsunto(s)
Administración Intravenosa/métodos , Aprobación de Drogas/legislación & jurisprudencia , Preparaciones Farmacéuticas/administración & dosificación , Disponibilidad Biológica , Ensayos Clínicos como Asunto , Análisis Costo-Beneficio , Relación Dosis-Respuesta a Droga , Semivida , Humanos , Farmacocinética , Valor Predictivo de las Pruebas , Estados Unidos , United States Food and Drug Administration/legislación & jurisprudencia , United States Food and Drug Administration/organización & administraciónRESUMEN
The investigation identified 10 publications that reported the individual values of total clearance (CL), renal clearance (CLr), nonrenal clearance (CLnr), and the glomerular filtration rate (GFR), in subjects with varying renal functions. We used these data to estimate extent and prevalence of changes in CLnr in chronic kidney disease (CKD) by examining the relationship between clearances and renal function. The investigation was restricted to drugs given intravenously and eliminated by mixed renal and nonrenal pathways. Six drugs showed a significant reduction of CLnr of 61% to 63% in subjects with severe renal impairment, suggesting that the decline of CLnr in advanced CKD can be clinically relevant and may not be uncommon. The decline of CLnr in CKD for these 6 drugs is linearly correlated with the decline of CLr. With 4 of the drugs studied, a significant reduction of CLnr in CKD was not seen. Renal clearance is a more reliable measure of renal function than GFR assessed by creatinine clearance. Chronic kidney disease affects the elimination more than the distribution of the 10 drugs.
Asunto(s)
Riñón/fisiopatología , Insuficiencia Renal Crónica/fisiopatología , Administración Intravenosa , Femenino , Humanos , Pruebas de Función Renal , Modelos Lineales , Masculino , Tasa de Depuración Metabólica , Farmacocinética , Insuficiencia Renal Crónica/complicacionesRESUMEN
Potassium is critical for maintaining cellular tonicity, propagation of nerve impulses, contraction of cardiac, skeletal, and smooth muscles, and normal renal function. The focus of this review is on the pharmacokinetics of potassium, K(+) , after administration of liquid and solid formulations of potassium chloride, KCl, to healthy subjects. Potassium can be considered an endogenous and exogenous compound. The amounts of endogenous K(+) are kept constant by balancing intake and loss of exogenous K(+) . Food and ingestion of KCl-containing medicines are sources for exogenous K(+) . In the pharmacokinetic context exogenous K(+) from KCl-containing medicines, K(+) exo,dose , is of primary interest. The distinction between the different K(+) entities is critical for obtaining unbiased estimates of the kinetic parameters for K(+) exo,dose . A literature search using prespecified acceptance criteria was performed. Publications were selected that reported plasma and urine data of K(+) exo,dose directly or provided information allowing their determination. Additional criteria applied included that the studies used a randomized design and controlled for the important covariates. Most of the selected publications reported urinary excretion data. Only 2 publications also reported plasma concentrations. The excursions of the plasma concentrations of K(+) exo,dose were considered too small to be of use by most investigators. The aggregate results indicate that urinary recovery data have the potential for providing reliable estimates for bioavailability and bioequivalence of K(+) exo,dose with KCl-containing formulations. Absorption efficiency, peak rates, and corresponding times of K(+) exo,dose with liquid formulations are fairly consistent among studies. The mean absorption efficiency of K(+) exo,dose with solid and liquid formulations of KCl ranges between 70% and 90%. The absorption rate of liquid formulations is rapid, whereas the solid formulations show extended release characteristics. The time-averaged renal clearance of K(+) exo,dose is about 200 mL/min during daytime and significantly smaller around midnight. Circadian rhythm and delayed homeostatic control of potassium make the pharmacokinetics of K(+) exo,dose time dependent. The impact of these endogenous controls makes the pharmacokinetics of K(+) exo,dose unusual.
Asunto(s)
Potasio/farmacocinética , Animales , Humanos , Riñón/metabolismo , Potasio/fisiología , Cloruro de Potasio/farmacocinética , Especificidad de la EspecieRESUMEN
This study evaluated the gastrointestinal absorption of fasudil, a novel Rho kinase inhibitor for the treatment of stable angina, at different sites using remote-controlled capsules and assessed the feasibility of developing an extended-release formulation. Ten healthy male volunteers were enrolled, and 8 subjects completed this single-dose, open-label, randomized, 5-way crossover study. Forty milligrams of fasudil HCl was administered as solution to the distal ileum and ascending colon, as powder to the ascending colon, and orally as an immediate-release tablet and solution. All treatments were well-tolerated and no serious adverse events were observed. The mean systemic availabilities of M3 relative to the oral solution were 1.04 (distal ileum, solution), 1.14 (ascending colon, solution), 1.27 (ascending colon, powder) and 1.04 (oral tablet), indicating similar systemic availability of M3 after administration of fasudil HCl to different gastrointestinal sites. The results suggest that development of a once-a-day extended-release formulation for fasudil HCl should be readily achievable.
Asunto(s)
1-(5-Isoquinolinesulfonil)-2-Metilpiperazina/análogos & derivados , Tracto Gastrointestinal/metabolismo , Absorción Intestinal/fisiología , Inhibidores de Proteínas Quinasas/metabolismo , Inhibidores de Proteínas Quinasas/farmacocinética , 1-(5-Isoquinolinesulfonil)-2-Metilpiperazina/administración & dosificación , 1-(5-Isoquinolinesulfonil)-2-Metilpiperazina/metabolismo , 1-(5-Isoquinolinesulfonil)-2-Metilpiperazina/farmacocinética , Adulto , Disponibilidad Biológica , Cápsulas , Estudios Cruzados , Humanos , Masculino , Persona de Mediana Edad , Inhibidores de Proteínas Quinasas/administración & dosificación , TelemetríaRESUMEN
An analysis of pH-induced changes of drug binding may contribute to the understanding of the mechanisms involved and the clinical relevance. A literature search was performed, and acceptance criteria set up, to select reported data for quantitative evaluation. The relationship between percentage of unbound drug, fu, and pH was analyzed, and the relevance of physicochemical characteristics of the ligand drugs and the importance of hydrogen ion-induced changes in plasma proteins for the pH sensitivity of the binding were evaluated. With all basic and the majority of acidic drugs, fu depended linearly on pH. Basic drugs showed a consistent behavior with fu decreasing with increasing pH. Acidic compounds behaved differently: With some, fu increased, and with others fu decreased, with pH, and with a third group of acids fu was pH independent. Large differences in the pH sensitivity of the plasma protein binding among individual compounds were found. The fu in plasma for some bases and acids increased up to 136% and 95%, respectively, at pH values seen in severe acidemia or alkemia. These changes in fu could be clinically relevant with narrow-therapeutic-range drugs. Physicochemical properties and other characteristics of the ligands affect the pH sensitivity of the interaction with plasma proteins, but there was clear evidence indicating that pH-induced changes in the plasma proteins are also involved in the observed pH-dependent interaction with ligands. It is generally accepted that the unbound, free fraction in whole blood or plasma is an important determinant of the pharmacokinetics and pharmacodynamics of drugs. pH-dependent protein binding and consequent changes in the free fraction have been reported for many drugs. From a basic science point of view, the systematic study of pH-induced perturbations of the drug-protein interaction may provide insight into the mechanism and forces involved in the binding of drugs to plasma proteins. From a clinical viewpoint it may be of interest to know the extent of pH-induced changes in the unbound fraction of drugs under extreme acidemic or alkalemic conditions. Arterial blood pH values compatible with life reportedly range between 6.7 and 8.0. pH values as low as 6.3 have been measured in survivors of drowning accidents. To the best knowledge of the authors, a review and interpretation of pH-associated changes in the protein binding of drugs has not been attempted to date. The goals of this investigation were to (1) review published results of studies that determined the impact of pH changes on the protein binding of drugs in man, (2) select representative data using predetermined criteria, (3) determine relevant factors impacting the pH sensitivity of the drug-protein interaction, and (4) attempt to interpret the results and their clinical relevance.
Asunto(s)
Proteínas Sanguíneas/efectos de los fármacos , Proteínas Sanguíneas/metabolismo , Concentración de Iones de Hidrógeno , Acidosis/metabolismo , Acidosis/fisiopatología , Alcalosis/metabolismo , Alcalosis/fisiopatología , Bases de Datos Bibliográficas , Bases de Datos Factuales , Humanos , Unión Proteica/efectos de los fármacos , Resultado del TratamientoRESUMEN
The goal of this investigation was to evaluate the performance of a novel method allowing estimation of absolute bioavailability from oral data only. In contrast to the traditional method, which compares areas under the drug concentration time curves after oral and intravenous administration in subjects with normal renal function, the novel method uses total and renal clearance values following oral administration from subjects with varying renal functions to estimate bioavailability. The novel method can also provide estimates for nonrenal clearance.Published data on total clearance and renal clearance of drugs obtained from subjects with variable renal functions were collected, the novel method applied, estimates of bioavailability and nonrenal clearance obtained and compared with reported estimates by the traditional methods. In addition computations were performed to assess various factors that could possibly affect the reliability of the novel method. The results indicated that the novel method provides accurate estimates for bioavailability of drugs meeting the prerequisites: linear kinetics, predominant renal excretion in normals, absence of metabolic polymorphism and independence of bioavailability and nonrenal clearance from renal function. The average (standard deviation) of the prediction error and bias of the bioavailability estimates by the novel method was 7.8 (6.0) and -1.4 (9.8)%, respectively. The estimates for nonrenal clearance by the novel method were less accurate. The computations confirmed that the estimates by the novel method are sensitive to renal-function dependent changes in nonrenal clearance and bioavailability and also depend on the extent of renal excretion of a drug. In conclusion, the novel method's main use is to diagnose absence or presence of changes in bioavailability and non-renal clearance of drugs in populations with varying renal function.
Asunto(s)
Bases de Datos Factuales/estadística & datos numéricos , Modelos Biológicos , Preparaciones Farmacéuticas/metabolismo , Administración Oral , Disponibilidad Biológica , Humanos , Modelos Lineales , Tasa de Depuración Metabólica/efectos de los fármacos , Tasa de Depuración Metabólica/fisiología , Estadística como AsuntoRESUMEN
UNLABELLED: A significant number of chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma and Waldenström's macroglobulinemia patients, treated with fludarabine phosphate (fludarabine), are elderly with diminished renal function. Since the kidney eliminates approximately 60% of fludarabine's primary metabolite (F-ara-A), dose modification is necessary for all patients with impaired renal function including elderly patients. In this study, 22 patients with varying levels of renal function received a single intravenous dose of fludarabine (25 mg/m3), followed one week later by five (one per day) doses that were adjusted according to three predefined creatinine clearance (CLcr) levels. Relationships between renal function and F-ara-A clearance, F-ara-A exposure and F-ara-A--related toxicities were examined. The results demonstrate that total F-ara-A clearance correlated with CLcr and that F-ara-A exposure levels and patient toxicity profiles were similar across treatment groups. IN CONCLUSION: The CLcr-based fludarabine dose adjustments used in this study provided reasonably equivalent F-ara-A exposure with acceptable safety in patients with varying degrees of renal function.